Last month, Roche announced that they are discontinuing two late-stage Phase III trials for the Alzheimer’s drug crenezumab, citing “disappointing” results.
The InvestAcure app implements spare-change investing for individuals to provide financial support for companies researching a cure to Alzheimer’s disease.
Over 10% of adults in the U.S. age 65 and older have Alzheimer’s and experts believe the number of people with the disease will continue to grow in the coming years. Millions of people hope
Max Tokarsky has made an active choice not to close his eyes. The Founder and CEO of InvestAcure is tackling a world problem head on and hopes his ingenious new app will help fund the discovery of lifesaving drugs.
Not exactly true, as the founder and CEO of InvestAcure is telling anyone who will listen. A former non-profit executive-turned-evangelist for the Impact Investment and Public Benefit Corporation model,